COVID-19: CDC, FDA and CMS Guidance

Jun 24, 2020
The Food and Drug Administration has partnered with the Critical Path Institute and National Center for Advancing Translational Sciences to launch the CURE Drug Repurposing Collaboratory, a forum for exchanging clinical practice data to inform potential new uses for existing drugs to treat unmet…
Jun 23, 2020
Hospitalization rates for COVID-19 were nearly four times higher for black, and two times higher for Hispanic, Medicare beneficiaries than for white Medicare beneficiaries, according to data on COVID-19 cases and hospitalizations released by the Centers for Medicare & Medicaid Services.
Jun 22, 2020
Clinical laboratories and health care providers should stop using any antibody tests on the Food and Drug Administration’s “removed” test list, evaluate prior results from the test and whether to retest the patient using an FDA-authorized test, the agency said.
Jun 22, 2020
A new study released by the Centers for Disease Control and Prevention shows emergency department visits dropped by 23% for heart attacks, 20% for strokes and 10% for hyperglycemic crises in first 10 weeks after the COVID-19 public health emergency declaration. 
Jun 22, 2020
A study of the first 20,000 adults hospitalized with severe or life-threatening COVID-19 to receive convalescent plasma found the investigational therapy safe in this diverse group of patients, according to findings from the Food and Drug Administration’s Expanded Access Program for COVID-19…
Jun 19, 2020
The Centers for Disease Control and Prevention recently updated its health care facility operations guidance to reflect the current COVID-19 pandemic environment.
Jun 18, 2020
Black COVID-19 patients were more likely to be hospitalized than white patients in a Centers for Disease Control and Prevention study that looked at cases in metropolitan Atlanta.
Jun 18, 2020
The Food and Drug Administration announced a public-private partnership to advance COVID-19 diagnostics.
Jun 17, 2020
The Food and Drug Administration issued updated templates for laboratories and manufacturers requesting emergency use authorization for molecular diagnostic tests that screen asymptomatic individuals for SARS-CoV-2 or use pooled samples.
Jun 16, 2020
The Food and Drug Administration said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir's antiviral activity.